FOSTER CITY, CA--(Marketwire - November 06, 2008) - SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported results for the third quarter ended September 30, 2008. Among the financial results reported by the biopharmaceutical company, revenue from product sales grew 52% to $14,328,000 over the same period last year, and net income rose to $773,000 or $0.02 per share on a basic and diluted basis, compared with a loss of $3.1 million or $0.07 per share in the third quarter of 2007. The company achieved a positive cash flow of $2,489,000 this last quarter.
